 |
|
Perioperative Management of Patients Receiving Oral Anticoagulants
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Dunn and Turpie1 provide a comprehensive review of studies that have evaluated various approaches to perioperative anticoagulation when warfarin sodium therapy needs to be interrupted to perform surgery. In their review, they consider the risks and benefits of using perioperative intravenous heparin or subcutaneous therapeutic-dose low-molecular-weight heparin (LMWH) as "bridging therapy," while patients are not orally anticoagulated. They conclude by recommending such bridging therapy for patients with mechanical mitral valves and for those with atrial fibrillation with a history of thromboembolic stroke. This recommendation assumes that, similar to warfarin therapy, intravenous heparin and therapeutic-dose LMWH reduce the risk of cardioembolism by about 75%. We made the same assumptions in a previous risk-benefit analysis of bridging therapy using intravenous heparin2; however, randomized trials have since disproved this assumption in patients with atrial fibrillation.3 Most notably, within 2 weeks of acute stroke, therapeutic-dose LMWH has been shown to be no more . . . [Full Text of this Article]
Clive Kearon, MB, PhD, FRCPC;
Jack Hirsh, MD, FRCPC
Hamilton, Ontario
RELATED ARTICLE
Perioperative Management of Patients Receiving Oral Anticoagulants—Reply
Andrew S. Dunn and Alexander G. G. Turpie
Arch Intern Med. 2003;163(20):2533.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Perioperative management of patients receiving vitamin K antagonists: [Prise en charge perioperatoire des patients traites aux antagonistes de la vitamine K]
Ickx and Steib
Canadian J. Anesthesia 2006;53:S113-S122.
ABSTRACT
| FULL TEXT
|
